One of the world’s leading cardiovascular medicine and transplantation centers uses Masimo’s SedLine ® Brain function monitor and O3 ™ Local oxygen saturation meter
Nathartel, Switzerland — (American business information) — Masimo (NASDAQ: MASI) announced today that the Deutsche Herzzentrum Berlin (DHZB) in Berlin, Germany, has adopted Masimo’s SedLine ® Brain function monitor and O3 ™ The local oxygen saturation meter technology is used to monitor patients in the operating room and intensive care unit.
This smart press release contains multimedia content. The full press release is available at:
Dr. Hermann Kuppe, the director and professor of the Department of Anesthesia of DHZB, said: “Our non-profit hospitals implement more than 32000 treatments every year. It is very important for our patients to conveniently access the advanced parameters and data provided by them. Many of these patients are undergoing particularly complex and critical operations. Masimo’s technology allows us to quickly access multiple parameters from a single monitor.”
The SedLine Brain Function Monitor provides 4 channels of EEG, which has helped clinicians better understand the effects of anesthesia on the brain. SedLine can monitor the effects of anesthesia and sedation on both cerebral hemispheres by monitoring electrical activity. The O3 local oxygen saturation meter can provide local oxygen saturation (rSO2) and reference arterial oxygen saturation (SpO2) information to help clinicians detect local hypoxemia that is easy to miss diagnosis with the pulse oxygen saturation meter alone.
Masimo Founder CEO Joe Kiani said: “The innovative treatment program of the Berlin Heart Center in Germany has helped it become one of the world’s leading cardiovascular medicine and transplantation centers. Every year, doctors, medical students and scientific researchers from all over the world apply to visit the center as clinical observers. We are glad to see that they use our SedLine and O3 technologies and are impressed by their focus on patient safety.”
DHZB is a specialized hospital dedicated to the diagnosis and treatment of cardiovascular and thoracic diseases, the implantation of mechanical circulatory support systems, and heart and lung transplantation. The hospital cooperates with the Berlin Charit é University Hospital to carry out more than 6700 operations every year, including 2400 operations using cardiopulmonary machines. DHZB treats more than 7200 inpatients and 24000 outpatients every year. The hospital has 194 beds, 71 of which are intensive care units. Since 2002, DHZB has passed the certification of National Quality Control Committee KTQ, which indicates that the high standard treatment provided by DHZB has been recognized. DHZB and its affiliates employ 1300 people, including 190 doctors and about 500 nurses.

@MasimoInnovates | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global leader in innovative non-invasive monitoring technology. Our mission is to improve patient outcomes and reduce treatment costs by introducing non-invasive monitoring into new sites and applications. In 1995, the company launched Masimo SET ® Mobile and Low Perfusion ™ (Measurement under low perfusion) Pulse oxygen saturation meter. Several studies have shown that this instrument can greatly reduce false alarms and accurately monitor true alarms. Masimo SET ® It is estimated that it has been applied to more than 100 million patients in the world’s leading hospitals and other medical institutions. In 2005, Masimo launched rainbow ® The technology of pulse carbon oxygen saturation meter realizes non-invasive continuous monitoring of blood components that can only be measured invasively in the past, including total hemoglobin (SpHb ®)、 Oxygen content (SpOC ™)、 Carboxyhemoglobin (SpCO ®)、 Methemoglobin (SpMet ®) And the latest Pulse Perfusion Variability Index (PVI ®) And oxygen reserve index (ORI ™), There are also SpO2, pulse rate and perfusion index (PI). In 2014, Masimo launched Root ®, This is an intuitive patient monitoring and connection platform, equipped with Masimo Open Connect ™ (MOC-9 ™) Interface. Masimo also relies on Radius 7 in the field of mHealth ™ Wearable patient monitor and MightySat ™ Fingertip pulse oxygen saturation meter and other products play an active leading role. For further information on Masimo and its products, please visit All published clinical studies on Masimo products can be found at 。

Forward looking statements

This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include SedLine regarding Masimo ® And O3 ™ Statement of potential efficacy of technology, etc. These forward-looking statements are based on current expectations of future events that affect us, and are subject to risks and uncertainties. All risks and uncertainties are difficult to predict, most of which are beyond our control, and may lead to our actual results being significantly different and diametrically opposite to those stated in our forward-looking statements, due to various risk factors, Including but not limited to risks related to the following factors: our assumptions about the repeatability of clinical results; Our belief in Masimo’s unique non-invasive measurement technology includes: Masimo’s SedLine related to positive clinical outcomes and patient safety ® And O3 ™ Technology; Our belief in Masimo’s non-invasive medical breakthrough to provide cost-effective solutions, which have the same accuracy and unique advantages, including immediate and continuous results, can achieve early treatment, and will not cause invasive trauma in all patients and each clinical situation; And other factors discussed in the “Risk Factors” section of our latest report to the Securities and Exchange Commission (“SEC”), which is available free of charge on the SEC’s website at Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct in the future. All forward-looking statements contained in this press release are in full compliance with the foregoing cautionary statements. We would like to remind you not to unduly rely on these forward-looking statements, which are only applicable today. Except as may be required by applicable securities laws, we have no responsibility to update, amend or clarify these statements or the “risk factors” contained in our latest report to the SEC, whether as a result of new information, future events or other matters.

The original version can be found on

Disclaimer: The original version of this announcement is officially authorized. The translation is only for the purpose of understanding. Please refer to the original version, which is the only version with legal effect.




805 Health Avenue, Medical High-Tech Industry Development Zone Taizhou


Copyright © 2015-2021 苏ICP备2022000416号